[Federal Register Volume 62, Number 162 (Thursday, August 21, 1997)]
[Notices]
[Page 44479]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-22164]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
National Institute on Drug Abuse (NIDA) Special Emphasis Panel 
meetings:

    Purpose/Agenda: To evaluate and review contract proposals.
    Name of Committee: NIDA Special Emphasis Panel (Controlled 
Release Parenteral Delivery System of Buprenorphine).
    Date: August 18, 1997.
    Time: 1:30 p.m.
    Place: Office of Extramural Program Review, National Institute 
on Drug Abuse, NIH, 5600 Fishers Lane, Room 10-49, Rockville, MD 
20857 (Telephone Conference).
    Contact Person: Mr. Eric Zatman, Contract Review Specialist, 
Office of Extramural Program Review, National Institute on Drug 
Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone 
(301) 443-1644.

    Name of Committee: NIDA Special Emphasis Panel (Preparation of 
Standardized Nicotine and Cigarettes for Addiction).
    Date: August 18, 1997.
    Time: 2:30 p.m.
    Place: Office of Extramural Program Review, National Institute 
on Drug Abuse, NIH, 5600 Fishers Lane, Room 10-49, Rockville, MD 
20857 (Telephone Conference).
    Contact Person: Mr. Eric Zatman, Contract Review Specialist, 
Office of Extramural Program Review, National Institute on Drug 
Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone 
(301) 443-1644.

    This notice is being published less than 15 days prior to the 
meetings due to the urgent need to meet timing limitations imposed by 
the review and funding cycle.
    The meetings will be closed in accordance with provisions set forth 
in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications 
and/or proposals and the discussions could reveal confidential trade 
secrets or commercial property such as patentable material and personal 
information concerning individuals associated with the applications 
and/or proposals, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, 
Drug Abuse Scientist Development, Research Scientist Development, 
and Research Scientist Awards; 93.278, Drug Abuse National Research 
Service Awards for Research Training; 93.279, Drug Abuse Research 
Programs, National Institutes of Health)

    Dated: August 13, 1997.
LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-22164 Filed 8-20-97; 8:45 am]
BILLING CODE 4140-01-M